Regal Investment Advisors LLC increased its stake in shares of Pfizer (NYSE:PFE) by 29.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,586 shares of the biopharmaceutical company’s stock after purchasing an additional 17,002 shares during the period. Regal Investment Advisors LLC’s holdings in Pfizer were worth $2,738,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of PFE. Delphi Private Advisors LLC raised its holdings in Pfizer by 84.3% in the 4th quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 1,600 shares during the last quarter. Americafirst Capital Management LLC acquired a new position in Pfizer in the 3rd quarter valued at $127,000. Oak Point Wealth Management acquired a new position in Pfizer in the 4th quarter valued at $165,000. Cerebellum GP LLC acquired a new position in Pfizer in the 4th quarter valued at $166,000. Finally, Lipe & Dalton raised its holdings in Pfizer by 6.9% in the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 71.33% of the company’s stock.
Shares of NYSE PFE opened at $37.06 on Wednesday. Pfizer has a 52-week low of $31.67 and a 52-week high of $39.43. The firm has a market cap of $218,053.44, a PE ratio of 13.98, a P/E/G ratio of 1.83 and a beta of 0.90. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same period in the previous year, the company earned $0.47 EPS. The business’s quarterly revenue was up .6% compared to the same quarter last year. sell-side analysts expect that Pfizer will post 2.96 EPS for the current fiscal year.
In related news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now directly owns 36,959 shares of the company’s stock, valued at approximately $1,374,505.21. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Charles H. Hill sold 42,393 shares of the company’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,037 shares of company stock valued at $9,064,785. 0.06% of the stock is owned by corporate insiders.
Several research analysts have weighed in on PFE shares. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price target for the company in a report on Monday, January 8th. BMO Capital Markets set a $39.00 price target on Pfizer and gave the company a “buy” rating in a report on Monday, January 8th. Morgan Stanley set a $41.00 price target on Pfizer and gave the company a “buy” rating in a report on Friday, January 5th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a report on Wednesday, January 17th. Finally, Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $39.20.
TRADEMARK VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/25/regal-investment-advisors-llc-raises-position-in-pfizer-pfe.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.